newsfilter
← Latest News
GlobeNewswire·

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing –